Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aclaris Therapeutics (ACRS) Free Cash Flow (2017 - 2025)

Aclaris Therapeutics has reported Free Cash Flow over the past 9 years, most recently at -$13.1 million for Q4 2025.

  • Quarterly results put Free Cash Flow at -$13.1 million for Q4 2025, down 46.17% from a year ago — trailing twelve months through Dec 2025 was -$47.1 million (down 133.38% YoY), and the annual figure for FY2025 was -$47.1 million, down 133.38%.
  • Free Cash Flow for Q4 2025 was -$13.1 million at Aclaris Therapeutics, down from -$11.0 million in the prior quarter.
  • Over the last five years, Free Cash Flow for ACRS hit a ceiling of $22.0 million in Q3 2024 and a floor of -$26.9 million in Q1 2023.
  • Median Free Cash Flow over the past 5 years was -$12.7 million (2024), compared with a mean of -$13.4 million.
  • Biggest five-year swings in Free Cash Flow: tumbled 223.24% in 2023 and later soared 191.1% in 2024.
  • Aclaris Therapeutics' Free Cash Flow stood at -$17.3 million in 2021, then dropped by 14.13% to -$19.7 million in 2022, then soared by 60.98% to -$7.7 million in 2023, then dropped by 16.17% to -$8.9 million in 2024, then crashed by 46.17% to -$13.1 million in 2025.
  • The last three reported values for Free Cash Flow were -$13.1 million (Q4 2025), -$11.0 million (Q3 2025), and -$10.0 million (Q2 2025) per Business Quant data.